FDG-PET/MRI 与盆腔 MRI 及胸腹部 CT 检测直肠癌患者同时性远处转移的诊断准确性比较
这项前瞻性研究纳入 101 例直肠腺癌初诊分期患者,比较全身 PET/MRI 与常规分期(盆腔 MRI 及胸腹部增强 CT)检测远处转移的准确性。PET/MRI 在所有患者中检测转移性疾病的准确性高于常规分期(88.4% vs. 82.6%,p=0.003),在伴肠壁外血管侵犯(EMVI)患者中同样更高(88.9% vs. 85.5%,p=0.013),且对全部病灶、肝脏、非区域淋巴结和肺部病灶的检出率均优于常规分期。
要点
- PET/MRI 检测转移性疾病的准确性为 88.4%,常规分期为 82.6%(p=0.003)。
- 伴 EMVI 患者中 PET/MRI 准确性 88.9%,常规分期 85.5%(p=0.013)。
- PET/MRI 将 19/33(57.5%)常规分期判定为不确定病灶的患者正确分类。
核心结论
- 在直肠癌伴 EMVI 患者的基线分期中,PET/MRI 检测同时性远处转移的准确性高于常规分期。
- PET/MRI 对非区域淋巴结、肝脏病灶和肺部病灶的检出率高于常规分期,并能正确分类常规分期判定为不确定病灶的患者。
研究设计与样本
- 前瞻性研究,2016 年 11 月至 2018 年 4 月纳入 101 例直肠腺癌初诊分期患者。
- 患者除接受常规分期(盆腔 MRI 及胸腹部增强 CT)外,还接受全身 PET/MRI 检查。
- 由不同阅片者分析常规分期与 PET/MRI 对原发肿瘤、淋巴结和转移分期的结果,记录转移灶的存在、数目和位置(非区域淋巴结、肝脏、肺或其他),每个器官病灶数限于 10 个,病灶定义为阳性、阴性或不确定。
- 采用 McNemar 检验比较准确性。
主要发现
- 所有患者中 PET/MRI 检测转移性疾病的准确性为 88.4%,常规分期为 82.6%(p=0.003)。
- 伴 EMVI 患者中 PET/MRI 准确性为 88.9%,常规分期为 85.5%(p=0.013)。
- 全部病灶检出率 PET/MRI 为 84.1%,常规分期为 68.9%(p=0.001)。
- 肝脏病灶检出率 PET/MRI 为 89.2%,常规分期为 84.2%;非区域淋巴结为 90.0% vs. 36.7%;肺部病灶为 76.4% vs. 66.9%。
- PET/MRI 将 19/33(57.5%)常规分期判定为不确定病灶的患者正确分类。
关键数值与推荐
- 病灶按器官(非区域淋巴结、肝脏、肺或其他)记录存在、数目和位置,每个器官病灶数限于 10 个。
- 病灶定义为阳性、阴性或不确定。
- 准确性比较采用 McNemar 检验。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compared the diagnostic accuracy of detecting distant metastases for baseline rectal cancer staging between PET/MRI and conventional staging (CS). MATERIALS AND METHODS: This prospective study from November 2016 to April 2018 included 101 rectal adenocarcinoma patients for primary staging. These patients underwent whole-body PET/MRI in addition to CS (pelvic MRI and thoracic and abdominal contrast-enhanced CT). Different readers analyzed CS and PET/MRI findings for primary tumor, nodal, and metastatic staging. The presence, number, and location of metastases were recorded according to the organ involved (non-regional lymph nodes (LNs), liver, lungs, or others). Lesions were defined as positive, negative, or indeterminate. The number of lesions per organ was limited to 10. The McNemar test was used to compare the accuracies. RESULTS: PET/MRI exhibited a higher accuracy in detecting metastatic disease than CS in all patients (88.4% vs. 82.6%, p = 0.003) and in patients with extramural vascular invasion (EMVI) (88.9% vs. 85.5%, p = 0.013). The detection rate of PET/MRI was superior to that of CS for all lesions [84.1% vs. 68.9%, p = 0.001], as well as those in the liver (89.2% vs. 84.2%), non-regional LNs (90.0% vs. 36.7%), and lungs (76.4% vs. 66.9%). PET/MRI correctly classified 19/33 (57.5%) patients with indeterminate lesions on CS. CONCLUSION: PET/MRI yields higher accuracy than CS for detecting distant synchronous metastases in the baseline staging of patients with rectal cancer and EMVI. PET/MRI exhibited a higher detection rate than CS for identifying non-regional LNs, hepatic lesions, and pulmonary lesions as well as correctly classifying patients with indeterminate lesions. TRIAL REGISTRATION: NCT02537340.
引用
- Queiroz MA, Ortega CD, Ferreira FR, et al. Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients. Eur J Nucl Med Mol Imaging. 2020. PMID: 32561971. doi:10.1007/s00259-020-04911-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。